Debra Odink insider trades: Anthera Pharmaceuticals (ANTH) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Debra reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 12, 2015 | ANTH | ↓ Sell | 1,205 | $6.15 | $7K | Direct | Oct 13, 2015 (1d) |
| Mar 1, 2012 | ANTH | ↓ Sell | 2,000 | $6.57 | $13K | Direct | Mar 5, 2012 (4d) |
| Feb 1, 2012 | ANTH | ↓ Sell | 2,000 | $7.67 | $15K | Direct | Feb 3, 2012 (2d) |
| Jan 10, 2012 | ANTH | ↓ Sell | 800 | $6.51 | $5K | Direct | Jan 12, 2012 (2d) |
| Jan 6, 2012 | ANTH | ↓ Sell | 1,200 | $6.50 | $8K | Direct | Jan 10, 2012 (4d) |
| Sep 24, 2010 | ANTH | ↑ Buy | 1,000 | $4.20 | $4K | Direct | Sep 24, 2010 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Debra Odink's insider trades
Debra Odink is Chief Technology Officer at Anthera Pharmaceuticals (ANTH). Since Sep 24, 2010, Debra has reported 1 open-market purchase worth $4K and 5 sales worth $49K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), shares withheld for taxes (5 filings), gifts (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ANTH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.